| Title | Argatroban for Preventing Occlusion and Restenosis after Extracranial Artery Stenting |
| Authors | Zhou, Lulu Liu, Dezhi Li, Yun Zhu, Wusheng Sun, Wen Li, Yongkun Xiong, Yunyun Chen, Zhaoyao Wang, Qizhang Cai, Qiankun Wang, Zhaolu Wang, Xiaomeng Sun, Wenshan Ge, Liang Ma, Minmin Li, Min Li, Hua Fan, Xinying Yin, Qin Xu, Gelin Liu, George Fan, Xiaobing Liu, Xinfeng |
| Affiliation | Southern Med Univ, Jinling Hosp, Dept Neurol, Nanjing 210002, Jiangsu, Peoples R China. Nanjing Univ, Jinling Hosp, Sch Med, Nanjing 210008, Jiangsu, Peoples R China. Nanjing Univ, Affiliated Hosp, TCM, Nanjing 210008, Jiangsu, Peoples R China. Guangzhou Med Univ, Shenzhen Shajing Peoples Hosp, Guangzhou, Guangdong, Peoples R China. Peking Univ, Hlth Sci Ctr, Inst Cardiovasc Sci, Beijing 100871, Peoples R China. Southern Med Univ, Jinling Hosp, Dept Neurol, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China. |
| Keywords | Argatroban Restenosis Thrombin Extracranial artery stenting RANDOMIZED CONTROLLED-TRIAL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY INTRACRANIAL ATHEROMATOUS DISEASE CORONARY BALLOON ANGIOPLASTY US MULTICENTER EXPERIENCE NEOINTIMAL PROLIFERATION ENDARTERECTOMY THROMBIN STENOSIS INJURY |
| Issue Date | 2014 |
| Publisher | 欧洲神经病学 |
| Citation | EUROPEAN NEUROLOGY.2014,71,(5-6),319-325. |
| Abstract | Background/Aims: Restenosis following extracranial artery stenting is a limitation that affects long-term outcomes. Effective and satisfying pharmacological strategies in preventing restenosis have not been established. This study aimed to evaluate whether argatroban, a direct thrombin inhibitor, could reduce the risk of in-stent restenosis after extracranial artery stenting. Methods: One hundred and fourteen patients hospitalized between August 2010 and August 2011 were enrolled. Patients were randomly assigned to argatroban (n = 58) and blank control groups (n = 56). The patients in the argatroban arm were treated with 10 mg of intravenous argatroban twice daily 2 days before and 3 days after the stenting procedures. Patients were followed for 12 months after the procedure. During follow-up, restenosis and target revascularization were analyzed. Recurrent cerebrovascular and cardiovascular events and deaths were also compared between the groups. Results: One patient in the stenting group withdrew immediately after the procedure due to unsuccessful stenting. Restenosis occurred in 4 patients (7.4%) in the argatroban group and in 11 patients (21.6%) in the control group during the 6- to 9-month angiographic follow-up period (p = 0.032). Nine months after the procedures, argatroban-treated patients had a trend towards a lower incidence of target revascularization compared with the controls (5.4 vs. 13.7%, p = 0.188). No major bleeding events or other adverse events occurred in the argatroban group. Conclusion: This pilot clinical trial is the first that uses argatroban to prevent restenosis in ischemic cerebrovascular disease, and suggests that intravenous administration of argatroban is effective and safe in preventing restenosis after extracranial artery stenting. Larger randomized controlled clinical trials are warranted. (C) 2014 S. Karger AG, Basel |
| URI | http://hdl.handle.net/20.500.11897/390584 |
| ISSN | 0014-3022 |
| DOI | 10.1159/000357866 |
| Indexed | SCI(E) |
| Appears in Collections: | 医学部待认领 |
